Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 1 10Phase 1/2 5Phase 3 4Phase NA 3Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1

Status

Completed 5Recruiting 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 29Thoracic 21Breast 14Other hematologic neoplasm 13Genitourinary 11Lymphoid 10Gynecologic 9Head & Neck 8Dermatologic 6CNS 6Sarcoma 5Myeloid 5Plasma cell 4Tumor-Agnostic 3Other 2Endocrine 2Other solid neoplasm 1NET 1Classical hematology 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Oxaliplatin 1Leucovorin 1Fluorouracil 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡